Amphastar Pharmaceuticals Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 5 of 5 Posts
Revance, Amphastar Named Top 2020 Specialty Pharmaceuticals Ideas At Wells Fargo
Article By: The Fly Wednesday, January 22, 2020 8:21 AM EDT
Wells Fargo analyst Jacob Hughes named Revance Therapeutics and Amphastar Pharmaceuticals his top ideas for 2020 in the Specialty Pharmaceuticals space.
In this article: AMPH, RVNC Also: AGN, EBS, JAZZ, PRGO, TEVA, MNK, BHC, OSMT, KRTX
Read
Cempra Plunges To 52-Week Low, Shire Drug Label Expanded
Article By: Arpita Dutt Friday, December 30, 2016 10:33 AM EDT
It was a relatively slow week for pharma stocks though a couple of companies suffered regulatory setbacks with the FDA issuing complete response letters (CRLs) for their regulatory applications.
In this article: AMPH, AZN, BMY, CEMP, MRK, MYL, SHPG
Read
Your Complete Guide To The Generic Drug Industry
Article By: Zacks Investment Research Wednesday, August 31, 2016 12:00 AM EDT
With some diseases, the range of safe concentration levels is incredibly narrow, which could make switching from name-brand to generic dangerous. But most generics are safe, and cheaper.
In this article: AGN, NVS, AKRX, MYL, PRGO, TEVA, AXGN, AMPH, GNRX
Read
Amphastar Pharmaceuticals - Chart Of The Day
Article By: Jim Van Meerten Thursday, March 5, 2015 5:58 PM EDT
Earnings estimated to compound at an annual rate of 5.00% for the next 5 years.
In this article: AMPH
Read
What This Upcoming Monday Means For MannKind Shareholders
Article By: Dr. Hung Tran Monday, August 11, 2014 8:59 AM EDT
As MannKind Corporation (NASDAQ: MNKD) prepares to release its earnings report on Monday, August 11, both investors and short sellers wait in suspense.
In this article: MNKD, AMPH
Read
1 to 5 of 5 Posts